MADRIGAL PHARMACEUTICALS INC's ticker is MDGL and the CUSIP is 558868105. A total of 41 filers reported holding MADRIGAL PHARMACEUTICALS INC in Q2 2017. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $2,347,000 | +249.8% | 8,375 | +233.5% | 0.00% | – |
| Q1 2024 | $671,000 | -56.8% | 2,511 | -62.6% | 0.00% | – |
| Q4 2023 | $1,553,000 | +379.3% | 6,715 | +202.2% | 0.00% | – |
| Q3 2023 | $324,000 | -87.7% | 2,222 | -80.5% | 0.00% | -100.0% |
| Q2 2023 | $2,630,000 | -16.3% | 11,388 | -12.2% | 0.00% | 0.0% |
| Q1 2023 | $3,143,000 | -17.7% | 12,971 | -1.4% | 0.00% | 0.0% |
| Q4 2022 | $3,817,000 | +454.8% | 13,150 | +24.3% | 0.00% | – |
| Q3 2022 | $688,000 | -8.4% | 10,580 | +0.8% | 0.00% | – |
| Q2 2022 | $751,000 | -31.4% | 10,497 | -5.8% | 0.00% | – |
| Q1 2022 | $1,094,000 | -1.4% | 11,149 | -15.0% | 0.00% | – |
| Q4 2021 | $1,110,000 | +76.5% | 13,110 | +66.5% | 0.00% | – |
| Q3 2021 | $629,000 | -16.2% | 7,873 | +2.3% | 0.00% | – |
| Q2 2021 | $751,000 | +1646.5% | 7,699 | +1997.8% | 0.00% | – |
| Q1 2021 | $43,000 | +168.8% | 367 | +154.9% | 0.00% | – |
| Q4 2020 | $16,000 | +6.7% | 144 | +14.3% | 0.00% | – |
| Q3 2020 | $15,000 | +114.3% | 126 | +106.6% | 0.00% | – |
| Q2 2020 | $7,000 | +16.7% | 61 | -32.2% | 0.00% | – |
| Q1 2020 | $6,000 | -81.8% | 90 | -74.6% | 0.00% | – |
| Q4 2019 | $33,000 | +312.5% | 355 | +285.9% | 0.00% | – |
| Q3 2019 | $8,000 | -20.0% | 92 | 0.0% | 0.00% | – |
| Q2 2019 | $10,000 | -33.3% | 92 | -24.6% | 0.00% | – |
| Q1 2019 | $15,000 | 0.0% | 122 | -8.3% | 0.00% | – |
| Q4 2018 | $15,000 | -81.9% | 133 | -66.0% | 0.00% | – |
| Q3 2018 | $83,000 | -96.8% | 391 | -95.8% | 0.00% | -100.0% |
| Q2 2018 | $2,598,000 | +139.0% | 9,291 | -0.1% | 0.00% | – |
| Q1 2018 | $1,087,000 | +26.0% | 9,304 | -1.0% | 0.00% | – |
| Q4 2017 | $863,000 | +100.7% | 9,401 | -1.6% | 0.00% | – |
| Q3 2017 | $430,000 | +14233.3% | 9,553 | +5008.6% | 0.00% | – |
| Q2 2017 | $3,000 | +200.0% | 187 | +315.6% | 0.00% | – |
| Q1 2017 | $1,000 | 0.0% | 45 | +7.1% | 0.00% | – |
| Q4 2016 | $1,000 | 0.0% | 42 | 0.0% | 0.00% | – |
| Q3 2016 | $1,000 | – | 42 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| University of Wisconsin Foundation | 73,487 | $17,003,422 | 28.29% |
| Tao Capital Management LP | 130,529 | $30,202 | 27.63% |
| Paulson & Co. | 1,105,741 | $255,846,353 | 23.09% |
| AlpInvest Partners B.V. | 211,488 | $48,934,093 | 11.18% |
| Bain Capital Life Sciences Investors, LLC | 324,619 | $75,110,344 | 7.20% |
| Avoro Capital Advisors LLC | 1,888,888 | $437,050,905 | 6.04% |
| Propel Bio Management, LLC | 30,032 | $6,948,804 | 5.76% |
| Baker Brothers Advisors | 1,969,798 | $455,771,861 | 5.19% |
| Rosalind Advisors, Inc. | 25,000 | $5,784,500 | 4.76% |
| TCG Crossover Management, LLC | 179,917 | $41,629,195 | 4.62% |